ERBB2 and breast cancer: In the BCSNR group, IBTR occurred in 24.4%, 6.1%, and 21.4% of patients with TNBC, luminal type breast cancer, and HER2-enriched breast cancer, respectively, while their counterparts in the MALND group experienced IBTR rates of 0.0%, 0.8%, and 7.1%, respectively.